1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,589 | 0,712 | 19:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.09. | NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie | 302 | Business Wire | Oral presentation selected by the SFT 2026 dedicated to the predictive biomarker associated with NFL-101 efficacy in smoking cessation Presentation of the results of a post-hoc analysis... ► Artikel lesen | |
| 28.07. | NFL Biosciences submits phase 2 smoking cessation trial to regulators | 1 | Investing.com | ||
| 28.07. | NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation | 446 | Business Wire | A Phase 2 clinical trial involving 310 smokers, designed to confirm the safety profile of NFL-102, determine its optimal dose, and evaluate its efficacy An adaptive design that allows for... ► Artikel lesen | |
| 07.07. | International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102 | 411 | Business Wire | Strengthening the international scientific recognition of NFL Biosciences' tobacco franchise within the leading scientific community dedicated to nicotine and tobacco research Oral presentation... ► Artikel lesen | |
| 30.06. | NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain | 407 | Business Wire | Validation of the entire GMP manufacturing chain for NFL-102, from extract production through to the lyophilized finished drug product Confirmation of NFL Biosciences' industrial capacity... ► Artikel lesen | |
| 01.06. | NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation | 349 | Business Wire | Identification of a biomarker predictive of efficacy, enabling a personalized approach to smoking cessation with NFL-101 In the target population, efficacy approximately 30% higher than... ► Artikel lesen | |
| NFL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 25.05. | NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application | 607 | Business Wire | Personalized medicine approach that could represent a first in smoking cessation Biomarker rooted in NFL-101's immunomodulatory mechanism of action Rigorous analytical validation... ► Artikel lesen | |
| 11.05. | NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101 | 364 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALNFL, a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today clarifies... ► Artikel lesen | |
| 04.05. | NFL Biosciences: International Scientific Community's Interest in NFL-102 for Smoking Cessation Confirmed by the Selection of Its Work at Two Leading Conferences | 423 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, announces that... ► Artikel lesen | |
| 15.04. | NFL Biosciences Presents Its 2025 Annual Results and Provides an Update on Its Clinical Progress Driven by a New Paradigm in Smoking Cessation | 549 | Business Wire | Emergence of a new paradigm in smoking cessation, based on an in-depth understanding of the biological mechanisms of addiction, with the ambition to achieve superior efficacy compared with current... ► Artikel lesen | |
| 15.04. | NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors | 617 | Business Wire | A €2.6 million bond financing has been secured with a group of European investors including Vester Finance, a shareholder of the Company Cash runway is immediately extended until the third... ► Artikel lesen | |
| 07.04. | A New Paradigm in Tobacco and Nicotine Addiction: NFL Biosciences Demonstrates the Mechanism of Action of NFL-102 in a Video | 401 | Business Wire | A breakthrough mechanism of action targeting neural plasticity associated with addiction, particularly through the CREB regulator, a key factor in relapse An educational video illustrating... ► Artikel lesen | |
| 11.03. | Bpifrance Renews Its Confidence in NFL Biosciences Through the Granting of a €500,000 Loan | 589 | Business Wire | €500,000 loan with a 36-month repayment deferral Financial support to prepare the submission of the Phase 2 clinical trial application for NFL-102 expected in mid-2026 Strengthening... ► Artikel lesen | |
| 19.02. | NFL Biosciences Publishes Its 2026 Financial Agenda | 472 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its financial agenda... ► Artikel lesen | |
| 26.01. | NFL Biosciences SA: NFL Biosciences Significantly Raises Its Efficacy Targets for Smoking Cessation | 498 | Business Wire | In-depth understanding of the mechanism of action of its drug candidates based on new data Enhanced clinical development strategy based on these advances, targeting clinical efficiencies... ► Artikel lesen | |
| 08.12.25 | NFL Biosciences Obtains Complementary Characterization Results for NFL-101, its first-in-class Drug Candidate for Smoking Cessation, and Prepares a New Patent Application | 402 | Business Wire | These results represent the first scientific milestone expected by regulatory agencies and potential pharmaceutical partners New patent application currently in preparation Results... ► Artikel lesen | |
| 12.11.25 | NFL Biosciences SA: NFL Biosciences Presents the Agenda for Results Expected by Regulatory Agencies and Potential Pharmaceutical Partners | 487 | Business Wire | Regulatory News:
NFL Biosciences SA (Euronext Growth Paris FR0014003XT0 ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today presents... ► Artikel lesen | |
| 20.10.25 | NFL Biosciences Outlines Its Development Plan for NFL-101 in Smoking Cessation Following Receipt of Scientific Advice From Several European Agencies and the U.S. FDA | 562 | Business Wire | Confirmation by several European agencies and the U.S. FDA of the relevance of the continuous abstinence validation criteria which showed statistical significance (p=0.02) in the Phase 2 CESTO... ► Artikel lesen | |
| 16.10.25 | NFL Biosciences Reports Its 2025 Half-Year Results and Provides an Update on Its Development | 699 | Business Wire | Additional studies and analyses confirming the excellent safety profile of NFL-101, its immunological action associated with smoking abstinence, and its rapid and sustained effects on brain regions... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,405 | +5,80 % | Qiagen-Aktie: Was die Spuren im Labor verraten - Warren Wise Podcast | Ein verlässliches Geschäft mit einer Zukunftsgeschichte, die Fragen aufwirft. Qiagen liefert den ersten Handgriff vieler molekularer Untersuchungen: Das Unternehmen löst Erbgut aus Blut, Gewebe oder... ► Artikel lesen | |
| CG ONCOLOGY | 67,38 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 39,640 | 0,00 % | Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days | ||
| TARSUS PHARMACEUTICALS | 73,00 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting | ||
| PRAXIS PRECISION MEDICINES | 295,78 | +0,09 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERA THERAPEUTICS | 30,420 | 0,00 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,755 | 0,00 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,225 | -0,06 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 10,500 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk | In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized... ► Artikel lesen | |
| MBX BIOSCIENCES | 58,51 | 0,00 % | Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential | ||
| EDGEWISE THERAPEUTICS | 41,400 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 27,790 | 0,00 % | Stifel reiterates Amylyx stock rating on avexitide confidence | ||
| KYMERA THERAPEUTICS | 107,37 | -0,02 % | B.Riley reiterates Kymera Therapeutics stock rating on new trial data | ||
| ADARX PHARMACEUTICALS | 18,250 | 0,00 % | HBM Healthcare Investments AG: HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments erhöht Beteiligung an der Portfoliogesellschaft ADARx Pharmaceuticals im Rahmen des Börsengangs... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,125 | +0,12 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen |
Das Unternehmen NFL BIOSCIENCES SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,586 Euro und damit -3,62 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NFL BIOSCIENCES SA finden Sie auf Wallstreet Online.